Hypnotic Drug Use and Chronic Obstructive Pulmonary Disease
Summary
Chronic obstructive pulmonary disease (COPD) affects hundreds of millions worldwide, imposing a substantial burden on patients and health systems. Insomnia, anxiety and mood disturbances are common comorbidities in COPD, often leading clinicians to prescribe hypnotic agents. While these drugs can facilitate sleep onset, they carry recognised risks in the context of compromised respiratory function. Hypnotics such as benzodiazepines and non-benzodiazepine sedative agents (Z-drugs) depress central respiratory drive, potentially exacerbating hypercapnia and precipitating acute respiratory failure in susceptible individuals. Moreover, observational data link hypnotic use to an increased frequency of COPD exacerbations and higher rates of hospital admission, suggesting that even short courses may heighten vulnerability to adverse outcomes.
Balancing sleep quality against respiratory safety presents a major clinical challenge. Non-pharmacological approaches, including cognitive behavioural therapy for insomnia, breathing exercises and optimised bronchodilator regimens, are recommended as first-line measures. When hypnotics are deemed necessary, lowest effective doses and careful monitoring of blood gases and symptom burden are essential. Recent efforts in pharmacovigilance and pharmacoepidemiology have sought to define risk profiles for different drug classes, with a view to tailoring therapy in older adults and those with severe airflow limitation. Future research aims to clarify dose–response relationships, identify safe prescribing thresholds and integrate sleep-promoting strategies that minimise respiratory compromise.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Hypnotic Drug Use and Chronic Obstructive Pulmonary Disease publication trend
The graph below shows the total number of articles in hypnotic drug use and chronic obstructive pulmonary disease across all publications each year (not limited to Nature Index journals).
Technical terms
Chronic Obstructive Pulmonary Disease (COPD): A progressive respiratory disorder characterised by airflow limitation and chronic inflammation of the airways.
Benzodiazepines: A class of sedative-hypnotic drugs that enhance inhibitory neurotransmission via γ-aminobutyric acid (GABA) receptors, depressing respiratory drive.
Z-drugs: Non-benzodiazepine hypnotics (e.g. zolpidem, zaleplon) with selective action at the GABA-A receptor, used to induce sleep.
Hypercapnia: An elevation of arterial carbon dioxide tension, often due to hypoventilation or impaired respiratory mechanics.
Acute exacerbation: A sudden worsening of respiratory symptoms in COPD, typically requiring additional therapy or hospitalisation.
References
- Drug Safety of Benzodiazepines in Asian Patients With Chronic Obstructive Pulmonary Disease. Frontiers in Pharmacology (2020).
- Mortality and concurrent use of opioids and hypnotics in older patients: A retrospective cohort study. PLOS Medicine (2021).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.